Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: EVISTA

Summary for Tradename: EVISTA

Suppliers: see list6
2013 Sales:$823,647,000
patent expirations by year for

Pharmacology for Tradename: EVISTA

Clinical Trials for: EVISTA

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Status: Completed Condition: Osteoporosis, Postmenopausal

Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
Status: Recruiting Condition: Negative Symptoms of Schizophrenia in Post-menopausal Women.

Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
Status: Completed Condition: Postmenopausal Osteoporosis; Compliance

Long Term Effects of Raloxifene Treatment on Bone Quality
Status: Completed Condition: Osteoporosis, Post-Menopausal

Cognition in the Study of Tamoxifen and Raloxifene
Status: Completed Condition: Cognition; Aging

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer

Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Status: Recruiting Condition: Polycystic Ovary Syndrome

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
Status: Completed Condition: Breast Cancer

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
Status: Completed Condition: Osteoporosis, Post-Menopausal

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
Status: Terminated Condition: Osteoporosis, Postmenopausal

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
raloxifene hydrochloride
TABLET;ORAL020815Dec 9, 1997RXYes<disabled><disabled>
raloxifene hydrochloride
TABLET;ORAL020815Dec 9, 1997RXYes5,478,847<disabled>Y<disabled>
raloxifene hydrochloride
TABLET;ORAL020815Dec 9, 1997RXYes5,811,120<disabled><disabled>
raloxifene hydrochloride
TABLET;ORAL020815Dec 9, 1997RXYes5,972,383<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology